Florilene Bouisset, n/a

Biostatistics Program Lead
Debiopharm International SA
Lausanne, Switzerland

Disclosure information not submitted.

Presentation(s):

• SAT-026 - Patient-Reported Outcomes of Debio 4126, A First 12-Week Formulation of Octreotide in Acromegaly Patients: Results from the OXTEND-01 Trial

  Saturday, June 13, 2026
  9:30 AM - 4:30 PM CT